Image

Feasibility and Acceptability of Endoscopic Mastectomy in Patients With Breast Cancer

Feasibility and Acceptability of Endoscopic Mastectomy in Patients With Breast Cancer

Recruiting
20-75 years
Female
Phase N/A

Powered by AI

Overview

Nipple -Sparing Mastectomy (NSM), with immediate breast reconstruction (IBR) can be offered to patients requiring mastectomy when the lesion is more than 2cm from the nipple. Endoscopic mastectomy is a technical alternative for small-volume breasts (cup sizes A, B, C), offering a NSM with IBR, but also concealing the scar on the axillary line. It can be performed with traditional laparoscopic equipment, making this technique much more accessible and less costly than robotic mastectomy. It uses a single-port device that is significantly less costly than robotic equipment.

Feasibility and safety studies remain limited to the Asian continent, and it would undoubtedly be beneficial to initiate research in Europe to add this new technical option to our surgical arsenal. This study project aims to explore the feasibility and safety of endoscopic nipple-sparing mastectomy for breast cancer indications in a French center.

Description

It s a practicability study, evaluating endoscopic approach for mastectomy, using an axillary single port in breast cancer patients. Conventional surgery conversion rate, operative time, infectious rate, esthetical outcomes, oncological safety and functional outcomes will be evaluated.

Eligibility

Inclusion Criteria:

  • Women between 20 and 75 years.
  • Patient with an indication for curative mastectomy, either unilateral or bilateral, with nipple preservation:
    • Extensive Carcinoma In Situ (CIS), more than 2 cm from the nipple
    • Multicentric Infiltrating Carcinoma (IC), more than 2 cm from the nipple
    • Large volume Infiltrating Carcinoma, more than 2 cm from the nipple
    • IC or CIS for which the patient refuses conservative treatment, more than 2 cm from the nipple
  • Breast volumes: cup sizes A, B, or C as defined by underwear size, and glandular

    ptosis not exceeding grade 2 according to Regnault's classification

  • Patient wishing to undergo immediate breast reconstruction.
  • WHO/OMS (World Health Organization/Organisation Mondiale de la Santé) performance status <3

Exclusion Criteria:

  • Cutaneous carcinoma
  • Inflammatory breast
  • History of oncological breast surgery on the same breast
  • Patient who has received radiation treatment on the same breast
  • Breast hypertrophy requiring a nipple-bearing flap
  • Smoking ≥ 10 cigarettes/day
  • BMI > 35
  • Protected patient or unable to give consent according to Article L1121-8 of the French Public Health Code (CSP).
  • Patient participating in another interventional clinical study.
  • ASA (physical status score of the American Society of Anesthesiologists) >2.
  • Pregnant or breastfeeding women according to Article L1121-5 of the CSP.
  • Vulnerable persons (those receiving psychiatric care, those deprived of liberty, and those admitted to a health or social institution) according to Article L1121-6 of the CSP.
  • Absence of effective contraception for patients of childbearing age.
  • Absence of affiliation with a social security scheme.
  • Absence of collected free, informed, and written consent.

Study details
    Breast Cancer

NCT06569706

University Hospital, Montpellier

3 September 2025

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.